Grove Bank & Trust Has $3.36 Million Stake in Abbott Laboratories $ABT

Grove Bank & Trust reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 19.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,799 shares of the healthcare product maker’s stock after selling 6,678 shares during the quarter. Grove Bank & Trust’s holdings in Abbott Laboratories were worth $3,358,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new position in Abbott Laboratories in the 2nd quarter valued at $3,026,180,000. Laurel Wealth Advisors LLC lifted its stake in shares of Abbott Laboratories by 13,347.0% during the second quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after acquiring an additional 6,011,891 shares during the period. Invesco Ltd. boosted its holdings in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after acquiring an additional 4,713,135 shares during the last quarter. First Trust Advisors LP boosted its holdings in Abbott Laboratories by 180.7% in the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after acquiring an additional 1,972,097 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in Abbott Laboratories by 51.0% in the third quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker’s stock worth $740,140,000 after purchasing an additional 1,865,250 shares during the period. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In related news, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last quarter. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Trading Down 1.5%

NYSE ABT opened at $105.58 on Friday. Abbott Laboratories has a one year low of $105.27 and a one year high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm has a market cap of $183.88 billion, a P/E ratio of 28.38, a P/E/G ratio of 1.68 and a beta of 0.74. The stock’s 50-day moving average is $112.75 and its 200-day moving average is $123.03.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same period in the previous year, the firm earned $1.34 EPS. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott expects to close its acquisition of Exact Sciences on March 23, 2026, after receiving all regulatory clearances — a major strategic move that immediately expands Abbott’s presence in cancer screening and diagnostics and could drive revenue growth over time. Abbott acquisition of Exact Sciences set to close on March 23, 2026
• Positive Sentiment: Coverage and commentary highlight the strategic expansion into diagnostics with Exact Sciences, positioning Abbott to capture a larger share of growing cancer-screening markets — a long-term revenue and pipeline positive. Abbott (NYSE:ABT) Expands Diagnostics With Exact Sciences Amid S&P 500 Futures
• Positive Sentiment: Independent bullish write-ups (syndicated on Yahoo/InsiderMonkey) recap a bullish thesis on ABT, citing valuation metrics and growth potential tied to diagnostics exposure — such coverage can support investor interest and longer-term upside. Is Abbott Laboratories (ABT) A Good Stock To Buy Now?
• Neutral Sentiment: Macro/theme-level research (UBS longevity thematic piece) frames aging and longevity as structural tailwinds for companies exposed to diagnostics and chronic-care solutions; this supports ABT’s long-term thesis but is not an immediate catalyst. Transformational Opportunities: UBS Suggests 2 Longevity Stocks to Buy as the $8T Aging Boom Accelerates
• Negative Sentiment: Healthcare stocks pulled back late Friday, dragging ABT with the sector; broader sector weakness can amplify short-term downside even when company-specific news is positive. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: Relative underperformance versus peers was noted in market reports — investors may be trimming ABT into the acquisition close due to integration, execution and dilution concerns. Abbott Laboratories stock underperforms Friday when compared to competitors

Analyst Ratings Changes

A number of research analysts have issued reports on ABT shares. Daiwa Securities Group cut their target price on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Argus dropped their price target on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Citigroup reduced their price objective on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Piper Sandler lowered their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. Finally, The Goldman Sachs Group dropped their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $136.16.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.